- Home
- RXRX vs IMVT Comparison
RXRX vs IMVT Comparison
Compare RXRX & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXRX
- IMVT
- Stock Information
- Founded
- RXRX 2013
- IMVT 2018
- Country
- RXRX United States
- IMVT United States
- Employees
- RXRX N/A
- IMVT N/A
- Industry
- RXRX Biotechnology: Pharmaceutical Preparations
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RXRX Health Care
- IMVT Health Care
- Exchange
- RXRX Nasdaq
- IMVT Nasdaq
- Market Cap
- RXRX 2.4B
- IMVT 2.7B
- IPO Year
- RXRX 2021
- IMVT N/A
- Fundamental
- Price
- RXRX $4.71
- IMVT $15.11
- Analyst Decision
- RXRX Buy
- IMVT Buy
- Analyst Count
- RXRX 4
- IMVT 11
- Target Price
- RXRX $7.25
- IMVT $33.88
- AVG Volume (30 Days)
- RXRX 17.0M
- IMVT 1.7M
- Earning Date
- RXRX 11-05-2025
- IMVT 11-06-2025
- Dividend Yield
- RXRX N/A
- IMVT N/A
- EPS Growth
- RXRX N/A
- IMVT N/A
- EPS
- RXRX N/A
- IMVT N/A
- Revenue
- RXRX $64,596,000.00
- IMVT N/A
- Revenue This Year
- RXRX $24.09
- IMVT N/A
- Revenue Next Year
- RXRX $20.99
- IMVT N/A
- P/E Ratio
- RXRX N/A
- IMVT N/A
- Revenue Growth
- RXRX 30.14
- IMVT N/A
- 52 Week Low
- RXRX $3.79
- IMVT $12.72
- 52 Week High
- RXRX $12.36
- IMVT $32.10
- Technical
- Relative Strength Index (RSI)
- RXRX 42.97
- IMVT 43.81
- Support Level
- RXRX $4.51
- IMVT $16.08
- Resistance Level
- RXRX $5.09
- IMVT $17.20
- Average True Range (ATR)
- RXRX 0.26
- IMVT 0.83
- MACD
- RXRX 0.04
- IMVT -0.04
- Stochastic Oscillator
- RXRX 40.63
- IMVT 22.22
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.